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Abstract The Bcl-2-related proteins Bcl-XL and Bcl-XS repre-
sent alternative splice products and exert opposite activities in
the control of apoptosis, but their signi¢cance for melanoma is
not yet clear. Applying the tetracycline-inducible expression
system Tet-On, we found overexpression of Bcl-XS by itself
su⁄cient to induce apoptosis in vitro in stably transfected hu-
man melanoma cell lines. Combination with proapoptotic agents
such as etoposide, pamidronate, and ceramide resulted in addi-
tive proapoptotic e¡ects, whereas Bcl-XL protected from apo-
ptosis caused via CD95/Fas stimulation. In nude mice growth of
melanoma xenotransplants derived from stably transfected cells
was signi¢cantly reduced after induction of Bcl-XS by doxycy-
cline. Our results indicate that Bcl-X proteins are of major
importance for control of apoptosis in malignant melanoma.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Melanoma is a highly malignant tumor developing from
transformed melanocytes or nevus cells. Since apoptosis de¢-
ciency is one mechanism of chemotherapeutic resistance as
shown for several human tumors [1], further understanding
of apoptotic signaling pathways appears helpful also for de-
veloping new therapeutic strategies. Important factors in reg-
ulation of apoptosis at the mitochondrial level are Bcl-2 pro-
teins which form a large family and segregate into two
functional groups of antiapoptotic proteins, such as Bcl-2,
A1, Mcl-1, Bcl-W, and Bcl-XL, as well as proapoptotic pro-
teins such as Bax, Bak, Bad, Bik/NBK, Bid, Bim, and Bcl-XS
[2,3]. The activity of several Bcl-2 proteins is considered to be
regulated through homo- and heterodimerization, suggesting
that their relative concentrations may act as a rheostat for cell
suicide programs [4,5]. Recently, it was reported that oligome-
rization of Bax and Bak to at least tetramers was required for
cytochrome c release from mitochondria [6,7]. The activity of
BH-3-only proteins, a large subgroup of proapoptotic Bcl-2
proteins, seems to be dependent on either Bax or Bak. Thus,
exogenous overexpression of Bik/NBK (Bcl-2 interacting kill-
er/natural born killer) triggers apoptosis only in Bax-positive,
but not in Bax-de¢cient cells as shown for colorectal cancer
cells [8].
The Bcl-X gene is expressed in several alternative splice
products including mRNAs for Bcl-XL and Bcl-XS [9,10].
Whereas Bcl-XL exerts antiapoptotic activity in the outer mi-
tochondrial membrane, Bcl-XS serves as a dominant negative
inhibitor of both Bcl-XL and Bcl-2 [11]. Another splice var-
iant, Bcl-XL, has been shown to interact with Bax but its
physiological role with respect to apoptosis control is still
unclear [12]. While it was shown to exert a proapoptotic ac-
tivity in rat promyeloid cells [9] it was antiapoptotic in mouse
neurons [13].
Recent investigations have presented evidence that in mel-
anoma cells pro- and antiapoptotic signaling cascades are at
least partially active [14], therefore, combination of chemo-
therapeutics and proapoptotic factors may represent a prom-
ising therapeutic strategy for melanoma. In previous studies,
we have shown that melanoma cell lines exhibit varying sen-
sitivities to agonistic activation of the CD95/Fas pathway as
well as to the sphingolipid ceramide [15]. Resistant melanoma
cells were generally characterized by a high Bcl-2/Bax ratio,
and the important role of this ratio was con¢rmed by stably
Bcl-2-transfected melanoma cell lines which became resistant
[4]. In the present study, we investigated the role of Bcl-XS
and of Bcl-XL for the regulation of apoptosis in melanoma
cells using tetracycline-regulated expression systems (Tet-On
and Tet-O¡) in vitro and in animal experiments in vivo.
2. Materials and methods
2.1. Cell culture
Normal human melanocytes (NHM) were isolated from human
foreskins after trypsin digestion, and were cultivated under serum-
free conditions as previously described [16]. Ten human melanoma
cell lines were investigated: A-375 [17]; Bro [18]; Mel-2a [19]; M-5
[20]; Mel-HO [21]; MeWo [22]; SK-Mel-13; SK-Mel-19; SK-Mel-23;
SK-Mel-28 [23]. They were maintained in Dulbecco’s modi¢ed Eagle’s
medium (4.5 g/l glucose; Gibco, Invitrogen, Karlsruhe, Germany)
supplemented with 10% fetal calf serum and antibiotics (Biochrom,
Berlin, Germany).
For induction of apoptosis, cells were treated for 10 h with 0.5 Wg/
ml of the agonistic anti-CD95 antibody CH-11 (IgM mouse mono-
clonal; Immunotech, Marseille, France) or with 20 WM C2-ceramide
in ethanol (Alexis, Gruenberg, Germany). Other cultures were treated
for 24 h with 100 Wg/ml pamidronate (3-amino-1-hydroxy-propyli-
dene-1,1-bisphosphonate; Novartis Pharmaceuticals, Basel, Switzer-
0014-5793 / 03 / $22.00 I 2003 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(03)01017-2
*Corresponding author. Fax: (49)-30-84452766.
E-mail address: eberle@medizin.fu-berlin.de (J. Eberle).
Abbreviations: NHM, normal human melanocytes; RT-PCR, reverse
transcriptase-polymerase chain reaction; PAGE, polyacrylamide gel
electrophoresis; PBS, phosphate-bu¡ered saline
FEBS 27666 9-10-03
FEBS 27666FEBS Letters 553 (2003) 250^256
land) or 2 WM etoposide in dimethyl sulfoxide (VP-16; Sigma, Tauf-
kirchen, Germany).
2.2. cDNA cloning and subcloning
Full-length cDNA for Bcl-XL and Bcl-XS was obtained by reverse
transcriptase-polymerase chain reaction (RT-PCR) starting with total
RNA of the melanoma cell line M-5 using primers corresponding to
the untranslated regions at the 5P end (TTGGACAATGGACT-
GGTTGA) and at the 3P end (GTAGAGTGGATGGTCAGTG) of
Bcl-X mRNA. The resulting cDNA fragments of Bcl-XL (765 bp) and
Bcl-XS (576 bp) were subcloned into the TOPO-TA plasmid (Invitro-
gen, Groningen, The Netherlands), and identity was con¢rmed by
restriction and sequence analysis. The cDNA fragments were further
subcloned into the EcoRI site of the pTRE-1 plasmid (Clontech, Hei-
delberg, Germany) downstream of a tetracycline-regulatable promoter
resulting in pTRE-Bcl-XS and pTRE-Bcl-XL.
2.3. Cellular transfection
For inducible gene expression, tetracycline-regulatable gene expres-
sion systems (Tet-On and Tet-O¡; Clontech) described by Gossen and
Bujard [24] were applied for melanoma cells. Tetracycline-controllable
regulation of apoptosis was investigated after transfection of Tet-On
and Tet-O¡ melanoma cell lines (SKM13-Tet-On, Bro-Tet-On and
Mel2a-Tet-O¡) with pTRE-Bcl-XL and pTRE-Bcl-XS. Tetracycline-
regulatable cell lines established by stable transfection of pTet-On
and pTet-O¡ plasmids (Clontech) into melanoma cell lines SK-Mel-
13, Bro, and Mel-2a, respectively, have been described previously [25].
In vitro promoter induction of Tet-On cell lines or repression of the
Tet-O¡ cell line Mel-2a was achieved by addition of doxycycline
(2 Wg/ml; ICN, Aurora, OH, USA) to the growth medium.
Transfections of melanoma cells were performed at a cellular con-
£uence of 50% using 0.5% Pfx-2 (Invitrogen) and 1.5 Wg/ml plasmid
DNA as described previously [26]. Stably transfected cell clones
were selected with 100 Wg/ml hygromycin (Life Technologies) and/or
400 Wg/ml geneticin (Boehringer, Mannheim, Germany). Individual
cell clones were obtained by limited dilution in microtiter plates and
were continuously cultured under antibiotic pressure. Stable SKM13-
Tet-On cell clones were established by transfection of pTRE-Bcl-XL
and pTRE-Bcl-XS. Clones were screened after transfection for mRNA
overexpression by Northern blot analysis, and two cell clones each
were further investigated (SKM13-Bcl-XS-3, -5 and SKM13-Bcl-XL-
11, -15). As controls, pTRE-1-transfected cell clones were generated
from SKM13-Tet-On (mock).
2.4. Quanti¢cation of apoptosis and cytotoxicity
For promoter induction, cells were treated with doxycycline for 48 h
immediately following transient transfection. Stably transfected cell
clones were induced with doxycycline also for 48 h at a cellular con-
£uence of 50%. Apoptosis was subsequently quanti¢ed by using a cell
death detection enzyme-linked immunosorbent assay (ELISA) (Roche
Diagnostics, Mannheim, Germany), which detects mono- and oligo-
nucleosomes formed in apoptotic cells according to a protocol de-
scribed previously [26]. Relative apoptotic rates were calculated as
the ratio of ELISA values between doxycycline-induced and non-in-
duced cells or by comparison to vector-transfected cells (pTRE-1).
Each assay consisted of triple values, and at least three independent
experiments were performed.
Cytotoxicity was determined in parallel by a lactate dehydrogenase
assay (Roche Diagnostics) as described previously [27].
2.5. Hoechst-33258 staining
Cells were harvested by trypsinization, ¢xed in 4% formaldehyde
(methanol-free) for 30 min at 4‡C and washed once with phosphate-
bu¡ered saline (PBS). 1 Wg/ml Hoechst-33258 dye (Sigma) was added
for 20 min at room temperature after which cells were washed again
with PBS. Cells were mounted (MoBiTec, Go«ttingen, Germany) and
examined by £uorescence microscopy. Apoptotic cells were identi¢ed
by condensed and fragmented nuclei. For quanti¢cation, a minimum
of 500 cells were counted, and the ratio of apoptotic cells was calcu-
lated as percent of total cells counted.
2.6. Expression analyses
Expression of mRNA was examined by Northern blot analysis and
by RT-PCR. The primers used for RT-PCR (for sequences see above)
enclosed the reading frames for both Bcl-XS and Bcl-XL and enabled
simultaneous mRNA ampli¢cation.
For protein extraction, cells were harvested 48 h after doxycycline
treatment of transient transfectants or stable cell clones, with lysis
bu¡er containing 50 mM Tris^HCl, pH 7.6, 150 mM NaCl, 1% Non-
idet P-40, 10% glycerine, 0.2% sodium dodecyl sulfate (SDS), 10 Wg/ml
trasylol (Bayer, Leverkusen, Germany), 1 mM phenylmethylsulfonyl
£uoride, 10 Wg/ml leupeptin and 5 Wg/ml pepstatin. Extracts were ho-
mogenized and centrifuged at 10 000Ug for 10 min. SDS^polyacryl-
amide gel electrophoresis (PAGE) and Western blot analysis of total
proteins were performed as previously described [26]. Western blots
were incubated with anti-Bcl-X polyclonal antibody (M-125, sc-1690;
Santa Cruz, Heidelberg, Germany; 1:200). Following incubation with
a peroxidase-labelled anti-rabbit secondary antibody (Dako, Ham-
burg, Germany; 1:5000), antigen^antibody complexes were detected
by ECL Western blotting detection reagents on Hyper¢lm ECL
(Amersham Pharmacia Biotech, Freiburg, Germany).
2.7. Animal studies
For inoculation, melanoma cells were harvested by brief incubation
with trypsin/EDTA, and subsequently trypsin was inactivated by
washing cells twice with growth medium containing 10% fetal calf
serum. Brie£y before inoculation, cells were washed again with PBS
and were ¢nally resuspended in PBS in a concentration of 106 cells/
200 Wl. Into both £anks of female BALB/c nu/nu mice at an age of
6^8 weeks (MpB, Ry, Denmark) each 106 cells (200 Wl) were injected
subcutaneously. For in vivo induction of the tetracycline-responsive
promoter, animals received doxycycline (2 mg/ml) in the drinking
water further enriched with 50 mg/ml sucrose beginning 1 day after
inoculation, whereas control mice received only sucrose-enriched
water. After tumors became visible, body weight and tumor size
were measured twice a week. For animal experiments, the guidelines
of the Federation of European Laboratory Animal Sciences Associa-
tions (FELASA) were applied.
3. Results
3.1. Bcl-XL is strongly expressed in melanoma cell lines in vitro
in contrast to Bcl-XS
Expression of Bcl-X proteins was investigated by Western
blot analysis in a series of eight human melanoma cell lines
and seven primary cultures of NHM. Strong expression levels
of Bcl-XL with a size of 29 kDa was seen in four melanoma
Fig. 1. Weak expression of Bcl-XS in human melanoma cell lines.
A: Protein expression was analyzed in eight melanoma cell lines
and in seven cultures of NHM. Each 60 Wg of protein lysates were
separated by SDS^PAGE (12%). The anti-human Bcl-X antibody
used recognizes both Bcl-XL and Bcl-XS, as shown by positive con-
trols of stably transfected melanoma cells (Bcl-XL-C and Bcl-XS-C),
however, Bcl-XS protein was not detectable in untransfected mela-
nocytic cells. A molecular weight marker is given on the left (M).
An extra band of 34 kDa obtained in some cell lines in this blot
was not reproducible in other Western blots. B: mRNA expression
of Bcl-XL and Bcl-XS was analyzed in six melanoma cell lines and
four cultures of NHM by means of RT-PCR. The PCR primers in-
cluded both coding regions to allow simultaneous ampli¢cation of
Bcl-XL (760 bp) and Bcl-XS (560 bp); L-actin was used as PCR
control (550 bp). As can be seen, melanoma cell lines showed a ten-
dency to stronger expression of Bcl-XL and weaker expression of
Bcl-XS as compared to NHM.
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cell lines (SK-Mel-13, Mel-HO, Bro, and A-375), whereas all
in vitro cultures of normal melanocytes investigated as well as
the remaining four melanoma cell lines revealed only moder-
ate expression. In contrast, Bcl-XS protein with a size of 20
kDa was not detectable in any of the melanocytic cell cultures
studied. Speci¢city of the used antibody for both Bcl-XL and
Bcl-XS was proven by using stably transfected cell clones as
positive controls (Fig. 1A). An extra band of 34 kDa obtained
in the blot shown in Fig. 1 was not reproducible in other
Western blots and may therefore result from unspeci¢c bind-
ing of the antibody used.
Northern blot analysis revealed a largely parallel expression
Fig. 2. Exogenous expression of Bcl-XS induces apoptosis in stably transfected melanoma cells. Cell clones resulted from stable transfection of
SKM13-Tet-On with pTRE-Bcl-XL (SKM13-Bcl-XL-11, -15), with pTRE-Bcl-XS (SKM13-Bcl-XS-3, -5), as well as with pTRE-1 plasmid
(mock-4 and mock-5). A: For Western blot analysis of total proteins, an antiserum speci¢c for both Bcl-XS and Bcl-XL was used. Equal
amounts of proteins (60 Wg) were loaded in each lane. Strong induction of Bcl-XS and Bcl-XL can be seen after doxycycline induction, whereas
mock-transfected cells were una¡ected. B: Apoptosis was quanti¢ed by determination of DNA fragmentation, and relative apoptotic rates were
calculated as the ratio of cells treated with doxycyline versus untreated cells. Relative apoptotic rates of untreated cells were separately set at 1.
Values represent the mean of a triple experimentR S.D., and each experiment was performed at least three times giving comparable results.
Fig. 3. Time-dependent induction of apoptosis by Bcl-XS. A: SKM13-Tet-On melanoma cells stably transfected with pTRE-Bcl-XS (Bcl-XS-5,
circles) and pTRE-Bcl-XL (Bcl-XL-15, triangles) were treated with doxycycline beginning at t=0, and relative apoptotic rates (¢lled symbols)
and cytotoxicity (open symbols) were determined at di¡erent times after induction. B: Parallel cultures were used for isolation of total cellular
protein and for subsequent Western blot analysis. Note that high expression of the Bcl-XL protein did not cause apoptosis and that Bcl-XS ex-
pression correlated with increased apoptosis but not with increased cytotoxicity.
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pattern for Bcl-XL mRNA, whereas Bcl-XS mRNA was also
not detectable in melanocytic cultures by Northern blot anal-
ysis (data not shown). Simultaneous RT-PCR ampli¢cation of
Bcl-XL and Bcl-XS mRNA proved expression of Bcl-XS in all
melanocytic cell cultures, however, its expression was signi¢-
cantly lower than that of Bcl-XL. Apparent weaker signals for
Bcl-XS were found in three melanoma cell lines (MeWo, A-
375, Mel-HO), as compared to normal melanocytes (Fig. 1B).
3.2. Inducible overexpression of Bcl-XS triggers apoptosis in
melanoma cell lines
Full-length cDNAs of Bcl-XL and Bcl-XS were cloned and
inserted into a tetracycline-regulatable expression plasmid re-
sulting in pTRE-Bcl-XL and pTRE-Bcl-XS. After transient
transfection of pTRE-Bcl-XS in the tetracycline-regulatable
melanoma cell lines SKM13-Tet-On and Mel2a-Tet-O¡, apo-
ptosis was signi¢cantly elevated by doxycycline induction in
SKM13-Tet-On (132R 4%) and respectively elevated by doxy-
cycline withdrawal in Mel2a-Tet-O¡ (167R 17%), as com-
pared to transfected non-induced cells. On the other hand,
transient transfection of Bcl-XL resulted in decreased basic
apoptotic rates in Mel2a-Tet-O¡ (62R 6%) and in Bro-Tet-
On (68R 5%) after induction. Western blot analysis performed
in parallel showed inducible overexpression of Bcl-XL and
Bcl-XS proteins after transient transfection, however, the ex-
pression level of both proteins was relatively low after tran-
sient transfection (data not shown).
After stable transfection of SKM13-Tet-On with pTRE-Bcl-
XL and pTRE-Bcl-XS, expression of Bcl-XS was induced 30^
40-fold in SKM13-Bcl-XS-3 and SKM13-Bcl-XS-5 after doxy-
cycline induction, and expression of Bcl-XL was induced
three-fold in SKM13-Bcl-XL-11 and SKM13-Bcl-XL-15 as
shown by Western blot analysis. Also, elevated expression
of Bcl-X proteins was seen without doxycycline treatment
(leakiness), which was more pronounced in Bcl-XL clones
(Fig. 2A). In parallel to Bcl-XS expression, apoptosis was
strongly enhanced by 2.7-fold and three-fold in Bcl-XS-3
and Bcl-XS-5 after doxycycline treatment (Fig. 2B).
Fig. 4. Induction of Bcl-XS in melanoma cells causes nuclear condensation and fragmentation. Cell clones resulted from stable transfection of
SKM13-Tet-On with pTRE-Bcl-XS (SKM13-Bcl-XS-5). A: Nuclear condensation and fragmentation were visualized by Hoechst-33258 staining.
24 h and 36 h after induction of Bcl-XS by doxycycline, a high proportion of cells showed clear indications of apoptosis (examples indicated
by arrows). B: The quantitative data represent mean values of triplicate experimentsR S.D.
FEBS 27666 9-10-03
A.M. Hossini et al./FEBS Letters 553 (2003) 250^256 253
Time kinetics revealed induced expression of Bcl-X proteins
in Bcl-XS-5 and Bcl-XL-15 as early as 8 h after addition of
doxycycline, and expression levels further increased up to 36 h.
This was paralleled by stepwise induced apoptosis in Bcl-XS-5,
whereas induction of Bcl-XL did not trigger apoptosis. Cyto-
toxicity determined in parallel was generally low for both
subclones at all times (Fig. 3).
Typical morphological signs of apoptosis (nuclear conden-
sation and fragmentation) were observed after labeling with
Hoechst-33258 in the cell clone Bcl-XS-5 24 h and 36 h after
induction of Bcl-XS (Fig. 4A). Cell counting revealed a high
number of apoptotic cells of 40R 7% (24 h) and 50R5% (36 h)
after Bcl-XS induction as compared to only 1^2% found in
non-induced cells (Fig. 4B).
3.3. Bcl-XS enhances the e¡ect of additional proapoptotic
stimuli, whereas Bcl-XL blocks CD95-induced apoptosis
When Bcl-XL expression was induced in two stably trans-
fected subclones of SKM13-Tet-On (Bcl-XL-11 and Bcl-XL-
15) by pre-incubation with doxycycline for 38 h, the proapo-
ptotic e¡ect of the CD95 agonistic antibody CH-11 seen in
mock-transfected cells was strongly antagonized. Also without
induction, a reduced apoptotic e¡ect of CH-11 was seen in
Bcl-XL-transfected cells, likely due to leaky expression from
the tetracycline promoter (Fig. 5A).
On the other hand, e¡ects of various proapoptotic stimuli
were signi¢cantly enhanced by concomitant expression of Bcl-
XS. Apoptosis induction showed an additive relation for the
combination with etoposide, pamidronate and ceramide, how-
ever, CH-11-induced apoptosis was only moderately enhanced
after Bcl-XS induction (Fig. 5B). This may result from the fact
that SKM13-Bcl-XS cells were already highly sensitive to CH-
11 without induction (Fig. 5B), as also shown for mock-trans-
fected cells (Fig. 5A).
3.4. Exogenous Bcl-XS expression inhibits melanoma growth in
mice
In animal experiments using subcutaneous injections of the
stably transfected Bcl-XS-5 melanoma cell clone, reduced tu-
mor growth was found when mice received doxycycline in the
drinking water for induction of Bcl-XS expression. In ¢ve
control mice large tumors had developed after 30 days, where-
as the average tumor size was seven times smaller in ¢ve
animals treated with doxycycline. Furthermore, melanoma
growth was further retarded up to day 51, when tumors
were still four times smaller in doxycycline-treated animals,
as compared to untreated controls (Fig. 6A). In contrast,
when control mice were inoculated with mock-transfected
cells, doxycycline treatment had no signi¢cant e¡ect on tumor
growth (data not shown). Interestingly, 7 weeks after inocu-
lation rapid tumor growth also appeared in doxycycline-
treated animals (Fig. 6B).
4. Discussion
In the present study we were able to show the relevance of
Bcl-X proteins for the regulation of apoptosis in human mel-
anoma cells. Bcl-XL is structurally and functionally closely
related to Bcl-2 [28], and its antiapoptotic function for certain
tumor cell types has been reported [29,30]. In our study we
detected high levels of Bcl-XL in human melanoma cell lines
at both the protein and the mRNA levels as compared to in
vitro cultures of NHM. Relatively high expression levels of
Bcl-XL and Bcl-2 have been reported in several tumor cell
entities such as in adenocarcinoma cells and in mammary
carcinoma cells [30^34]. In melanoma cells, expression of
Bcl-XL was investigated earlier at the mRNA level by RT-
PCR, and the degree of its expression seemed to be correlated
with tumor progression [35].
Our present data indicate that exogenous overexpression of
Bcl-XL leads to signi¢cant reduction of basic apoptotic rates
in melanoma cells and can confer partial resistance to CD95-
induced apoptosis. Also in mammary carcinoma cells Bcl-XL
overexpression neutralized the proapoptotic e¡ect of CD95
ligand and tumor necrosis factor-K [36], and in neuroblastoma
cells, high expression of Bcl-XL was shown to be responsible
for chemoresistance and tumorigenicity [29,32]. Finally, in-
creased chemoresistance against cisplatin had been found after
exogenous overexpression of Bcl-XL in a melanoma cell line
[37].
The mechanism of apoptosis induction by Bcl-XS is largely
unknown and may partially depend on dominant negative
inhibition of Bcl-XL and Bcl-2 [11,38]. According to our in-
vestigations, Bcl-XS was only weakly expressed in melanocytic
cells and even showed a tendency to lower expression in mel-
Fig. 5. Bcl-XS increases the e¡ect of proapoptotic stimuli, whereas
Bcl-XL inhibits CD95-dependent apoptosis. A: Two SKM13-Tet-On
subclones expressing Bcl-XL after doxycycline treatment (Bcl-XL-11
and Bcl-XL-15) and a vector-transfected control clone (mock) were
grown without doxycycline (a,b) or were preincubated with doxycy-
cline for 38 h (c,d). For induction of apoptosis, cells were treated in
addition with the agonistic CD95 antibody CH-11 for another 10 h
(b,d). Relative apoptotic rates were calculated in relation to un-
treated mock cells, which were set at 1. B: The SKM13-Tet-On sub-
clone Bcl-XS-5 expressing Bcl-XS after doxycycline treatment was
preincubated for 24 h or 38 h with doxycycline (black columns) or
left without (white columns). After preincubation, cells were treated
in addition with di¡erent proapoptotic stimuli for a further 10 h
(CH-11, ceramide) or for 24 h (etoposide, pamidronate). Relative
apoptotic rates were calculated with respect to untreated cells, which
were set at 1. Values of A and B represent the mean of triple exper-
imentsR S.D.; each experiment was performed at least three times
giving comparable results.
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anoma cell lines, as compared to cultures of normal melano-
cytes. Weak expression of Bcl-XS was also found for other
tumor cells such as mammary carcinoma and neuroblastoma
[39,40], and no Bcl-XS expression had been reported for an-
other panel of four melanoma cell lines [41].
Tetracycline-regulatable gene expression o¡ers several ad-
vantages such as high inducibility and fast response times
[42]. Possible pleiotropic e¡ects of doxycycline on melanoma
cells were ruled out in our experimental system by utilizing
both Tet-O¡ and Tet-On melanoma cell lines in transient
transfections. The stable transfections were performed with
a Tet-On cell line derived from SK-Mel-13 which is charac-
terized by an average melanocytic di¡erentiation status [43].
Leakiness of the tetracycline-regulatable promoters as seen
here in melanoma cells had been reported previously [44],
and was explained by absence of chromatin repression, high
copy numbers, and possibly nearby enhancers [45].
By using the Tet-On gene expression system, we showed
that apoptosis can be triggered in stably transfected melano-
ma cells by induction of Bcl-XS expression, and the combina-
tion of Bcl-XS expression with additional apoptotic stimuli
such as etoposide [46], ceramide [47], pamidronate [48], and
agonistic CD95 activation [15] resulted in additive proapo-
ptotic e¡ects.
The induction of apoptosis resulted from a high proportion
of apoptotic cells as shown by chromatin staining which is a
generally accepted technique for identi¢cation of apoptotic
cells [49,50]. In accordance with these data, adenovirus-medi-
ated expression of Bcl-XS had been reported to induce apo-
ptosis in mammary carcinoma and neuroblastoma cells
[39,40,51]. A sensitization to chemotherapeutics by overex-
pression of Bcl-XS as shown here for melanoma has only
been described for MCF-7 mammary carcinoma cells when
treated with either taxol or etoposide. In MCF-7 Bcl-XS over-
expression, however, was not able to trigger apoptosis by itself
after stable transfection [46].
The signi¢cance of apoptosis induction by Bcl-XS for re-
duced melanoma tumorigenicity was demonstrated in vivo in
human xenotransplants on nude mice. Induction of Bcl-XS
resulted in reduced tumor size and delayed tumor develop-
ment. Recovered tumor growth after 7 weeks may be driven
by acquired resistance of the tumor cells to Bcl-XS-induced
apoptosis, but the basis for developing resistance still remains
unclear. Inhibition of tumor growth due to Bcl-XS expression
in vivo has been reported only for MCF-7 mammary carcino-
ma cells after repeated intratumoral injection of Bcl-XS ad-
enovirus [40].
Our data underline the decisive role of Bcl-X proteins for
the regulation of apoptosis in melanoma. The strong pro-
apoptotic e¡ect of exogenous Bcl-XS expression in melanoma
cells both in vitro and in vivo, shown here for the ¢rst time,
may be of further value for therapeutic approaches against
melanoma. Particularly the additive proapoptotic e¡ect of
Bcl-XS in conjunction with various chemotherapeutics ap-
pears promising for combination therapies.
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